DHC is a high-risk, high-upside senior-housing turnaround where demographic tailwinds and SHOP recovery could unlock major value, but leverage and external management remain material constraints.
Diversified Healthcare Trust (DHC) is an institutional real estate investment trust (REIT) specializing in high-quality healthcare and life science properties across the United States.[1, 2] Headquartered in Newton, Massachusetts, the company’s day-to-day operations and capital allocation strategies are externally managed by The RMR Group (Nasdaq: RMR), an alternative asset management firm with extensive institutional real estate experience.[1, 3] DHC’s real estate portfolio is strategically structured to capitalize on the secular demand trends spanning the healthcare, medical clinical research, and senior housing sectors, with assets distributed across several distinct operational segments.[2, 4]
As of the first quarter of 2026, DHC’s real estate portfolio consists of 285 properties located across 33 states and Washington, D.C..[4, 5] This footprint encompasses 23,901 senior living units, approximately 5.6 million square feet of medical office and life science properties, and accommodates approximately 250 tenants.[4, 5] The company's operations are segmented into three primary divisions that dictate its revenue generation and capital exposure [6, 7]:
| Segment | Revenue Source | Asset Composition | Operator Structure |
|---|---|---|---|
| Senior Housing Operating Portfolio (SHOP) [7, 8] | Direct resident fees and care services [7] | 199 properties containing 22,573 senior living units [7] | Managed by third-party regional operators under fee-based agreements [9, 10] |
| Medical Office & Life Science Portfolio [2, 4] | Long-term commercial triple-net leases [6] | 5.6 million square feet of laboratory and clinical properties [4, 5] | Leased directly to clinical systems and biotech researchers [2, 4] |
| Triple-Net (NNN) Lease Senior Living [6, 11] | Fixed rental payments from single-tenant operators [6] | Standalone senior living facilities leased to external operators [6, 11] | Single-tenant operators responsible for all property expenses [6] |
DHC's primary customer types vary by segment, spanning private-pay senior citizens and their families in the SHOP portfolio, healthcare systems and clinical groups in the medical office buildings, and institutional biotechnology researchers in the life science properties.[2, 5, 6] These customers select DHC over alternatives due to the strategic geographical alignment of its assets, the high physical specialization of its facilities, and the operational stability provided by its diversified regional operating partners.[1, 10, 12]
DHC’s operational recovery and financial trajectory are primarily governed by three variables: occupancy absorption, rate growth, and disciplined property-level expense management within its SHOP segment.[5, 8] Following several years of structural disruption in the senior living industry, the company has pivoted from asset rationalization to an aggressive operational optimization campaign.[10, 11]
The transition of 116 senior living communities in late 2025 from AlerisLife to seven highly specialized regional operators marked a critical turning point for the company.[9, 10] By aligning its properties with operators that possess deep regional market clusters and local labor procurement networks, DHC has driven rapid occupancy gains and implemented localized care-level pricing increases.[10, 12]
Operational performance is further supported by structural expense controls.[5, 8] During the first quarter of 2026, the company successfully negotiated new dietary, food, and beverage contracts while rightsizing regional labor structures, effectively lowering property-level cost structures and expanding operational margins.[11]
DHC possesses a moderate, localized economic moat characterized by high regulatory barriers, significant physical asset specialization, and high tenant switching costs.[2, 6, 13] In the medical office and life science portfolio, properties are situated near clinical hospital campuses and research hubs.[14, 15] This proximity creates high switching costs, as clinical providers rely on physical convenience for patient access, and laboratory tenants require heavily customized, capital-intensive infrastructure that cannot be easily replicated.[2, 6]
In the senior housing segment, the moat is reinforced by state-level Certificate of Need (CON) regulations, which restrict the construction of competing senior living facilities in established submarkets.[13]
Furthermore, senior communities face steep operational switching costs; moving elderly residents to competing facilities is highly disruptive, resulting in natural customer retention once occupancy is established.
DHC is externally managed by RMR and relies on third-party operators for its SHOP assets.[1, 3] Thus, it lacks the proprietary technology-driven and centralized operating platforms that define the competitive advantages of larger peers like Ventas’s proprietary Operational Insights platform.[1, 3, 12]
The market opportunity for healthcare real estate is supported by powerful macroeconomic demographic shifts.[13, 16] The United States is experiencing an unprecedented surge in its senior population as the approximately 70 million Baby Boomers begin turning 80 years old in 2026.[12, 16] This demographic cohort is projected to drive a 29% expansion in the 80+ age bracket over the next five years, compared to a mere 4% expansion observed in the preceding five years.[12]
Importantly, this demand surge coincides with severe structural undersupply.[5, 12] High interest rates and tight construction financing have restricted new senior housing development, with projected new unit deliveries in 2026 limited to approximately 10,000 units—a massive decline from the peak construction levels of roughly 30,000 units annually between 2016 and 2020.[12] This demand-supply imbalance gives DHC immense pricing power and an extended runway for organic occupancy recovery.[5, 12]
DHC operates within a highly competitive healthcare REIT landscape, dominated by massive institutional peers such as Welltower Inc. (NYSE: WELL) and Ventas, Inc. (NYSE: VTR), alongside specialized mid-cap operators like Healthpeak Properties (NYSE: DOC) and National Health Investors (NYSE: NHI).[15, 17]
| Peer Company | Market Capitalization | Key Competitive Advantage | Operational Posture (2026) |
|---|---|---|---|
| Welltower Inc. (WELL) [17, 18] | \$144.68 Billion | Institutional scale, international diversification, low leverage [15, 18] | Aggressive capital deployment and guidance raises [18] |
| Ventas, Inc. (VTR) [16, 17] | \$38.82 Billion | Collaborative OIT™ data platform, operator local market clusters [12] | Multi-billion-dollar acquisition campaign [16] |
| Diversified Healthcare Trust (DHC) [17, 19] | \$2.25 Billion | Specialized regional operators, asset rehabilitation upside [10, 11] | Deleveraging, organic recovery, acquisitions on hold [11] |
DHC is currently positioned as a high-leverage turnaround play relative to its industry peers.[11, 20] While Welltower and Ventas boast superior balance sheets and higher stabilized occupancies (with Welltower’s same-store SHOP occupancy at 88.8% and Ventas’s at 87.0% in Q1 2026) [12, 16, 18], DHC’s lower same-property occupancy of 82.4% represents a "coiled spring" opportunity.[8, 11]
Because DHC’s operational baseline is lower, any incremental increase in senior housing occupancy generates superior percentage gains in Net Operating Income (NOI) and Normalized Funds From Operations (FFO) relative to its stabilized competitors.[5, 11]
However, DHC is currently holding its ground rather than rapidly expanding, as its elevated leverage of 7.8x restricts it from competing in the aggressive, multi-billion-dollar external acquisition campaigns currently being waged by Ventas and Welltower.[11, 12, 16, 18]
DHC announced its first-quarter 2026 financial results on May 4, 2026, with the corresponding earnings call held on May 5, 2026.[1, 2, 19] The reported quarterly results presented a divergent picture, characterized by GAAP-level bottom-line misses alongside strong non-GAAP operational outperformance.[8, 11]
DHC Q1 2026 Net Operating Income (NOI) Segment Breakdown:
Total NOI: $75.92M [7]
├── SHOP Segment NOI: $43.63M (57.5%) [7]
├── Medical Office & Life Science NOI: $25.06M (33.0%) [7]
└── All Other Segments NOI: $7.23M (9.5%) [7]
The segment-level performance was anchored by the Senior Housing Operating Portfolio (SHOP), which drove same-property SHOP NOI growth of 13.5% year-over-year to \$44.3 million.[8, 11] When adjusted for non-recurring insurance proceeds received in Q1 2025, same-property SHOP NOI actually surged by 22% year-over-year.[11]
This SHOP outperformance was driven by same-property occupancy growth of 110 basis points year-over-year to 82.4%, and average monthly rate growth of 5.9%.[8, 11] Conversely, the Medical Office and Life Science portfolio remained highly stable, posting same-property occupancy of 95.3% and generating \$25.4 million of segment NOI.[11]
To reconcile the divergence between the GAAP net loss and operational cash flow, the following table details the adjustments used to calculate Net Operating Income (NOI) for the three months ended March 31, 2026 [7]:
| Reconciliation Item | Three Months Ended March 31, 2026 (USD in Thousands) |
|---|---|
| Net Loss [7] | \$(43,275) |
| Equity in Net Earnings of Investees [7] | \$(96) |
| Income Tax Expense [7] | \$622 |
| Loss Before Income Taxes and Investees [7] | \$(42,749) |
| Interest Expense [7] | \$37,045 |
| Interest and Other Income [7] | \$(233) |
| Loss on Sale of Real Estate [7] | \$1,207 |
| Acquisition and Transaction-Related Costs [7] | \$3,693 |
| General and Administrative [7] | \$14,038 |
| Depreciation and Amortization [7] | \$62,914 |
| Net Operating Income (NOI) [7] | \$75,915 |
During the Q1 2026 earnings call, CEO Christopher Bilotto highlighted DHC’s shift in capital allocation from completing operator transitions to executing high-ROI capital improvement projects.[11] The company has initiated a pipeline of opportunities across 16 communities.[11]
The initial phase includes six projects focused on converting underutilized skilled nursing wings into higher-margin assisted living and memory care units, budgeted at \$20 million.[8, 11] These projects are projected to be immediately accretive to earnings upon completion, targeting returns starting in the mid-teens.[11]
Management reiterated that all near-term acquisitions remain on hold, with capital deployment strictly prioritized toward reinvesting in existing assets and organic deleveraging.[8, 11]
During the latest quarterly earnings call on May 5, 2026, management originally reaffirmed the full-year 2026 guidance ranges established during the fourth-quarter 2025 earnings call.[11]
These ranges projected full-year SHOP NOI of \$175 million to \$185 million, Adjusted EBITDAre of \$290 million to \$305 million, and Normalized FFO of \$0.52 to \$0.58 per share.[11] This conservative posture reflected caution regarding operator transitions and ongoing cost containment.[10, 11]
However, on June 1, 2026, DHC issued a substantial upward revision to its full-year 2026 financial guidance, driven by rapid expense savings and accelerated procurement efficiencies.[5, 22]
| Financial Metric | May 5, 2026 Reaffirmed Guidance [11] | June 1, 2026 Revised Guidance [5, 22] | Implied Performance Acceleration |
|---|---|---|---|
| SHOP NOI | \$175M – \$185M | \$185M – \$195M | Midpoint increase of 5.5% |
| Total Portfolio NOI | \$297M – \$313M | \$307M – \$323M | Midpoint increase of 3.3% |
| Adjusted EBITDAre | \$290M – \$305M | \$300M – \$315M | Midpoint increase of 3.4% |
| Normalized FFO Per Share | \$0.52 – \$0.58 | \$0.56 – \$0.62 | Midpoint increase of 7.3% |
This revised SHOP guidance is supported by expectations of a 300 basis point expansion in year-over-year occupancy, revenue growth of approximately 8.0%, and average monthly rate increases of 5.3%, partially offset by operating expense growth of 4.5%.[5, 22]
The Q1 earnings release on May 4, 2026, met with a constructive market response, with the stock climbing 0.76% in premarket trading as investors prioritized the non-GAAP FFO and EBITDA outperformance over the GAAP net loss miss.[8]
The subsequent guidance revision on June 1, 2026, had a more pronounced market impact.[20, 23] Shares rose 0.97% to \$8.29 in post-market trading immediately following the announcement and continued to rally throughout June, touching a fresh 52-week high of \$9.62 on volume nearly three times its daily average.[20, 23]
Wall Street analysts responded with immediate price target upgrades.[20, 24] B. Riley Securities raised its target from \$8.50 to \$11.00 (maintaining a Buy rating) on June 9, 2026, citing robust expense savings and a runway for strong NOI growth well beyond 2026.[20, 24] RBC Capital lifted its target from \$6.00 to \$8.00 on June 18, 2026, highlighting solid progress repositioning the SHOP portfolio.[20, 24]
Additionally, Zacks upgraded DHC to a Rank #2 (Buy) on June 18, 2026, reflecting the positive trajectory of earnings estimates, bringing the consensus average target to \$9.83.[24, 25]
To evaluate DHC’s valuation, investors must focus on several core metrics beyond standard multiples.[21, 26] The company’s 5-year sales growth rate stands at -1.18%, reflecting a multi-year period of asset rationalization, non-core property liquidations, and the structural impact of the pandemic on senior living occupancies.[26, 27]
Connecting DHC's valuation directly to its operational structure reveals three distinct discount factors that explain why the company trades at a discount to peers like Ventas and Welltower [17, 28]:
The primary execution risk centers on the ongoing stabilization of the SHOP portfolio following the transition of 116 senior living communities to seven regional operators.[9, 10] While early results suggest meaningful cost savings and occupancy traction, any operational friction, local labor disputes, or failure by these operators to maintain care standards would impair DHC’s brand and reverse same-property NOI progress.[4, 8, 13]
Furthermore, DHC is executing a specialized \$20 million wing conversion and capital improvement program.[11] These projects are highly complex, requiring local zoning approvals, Certificate of Need compliance, and construction management.[11, 13] Delays or cost overruns would directly compress expected mid-teens returns.[11]
DHC is heavily outmatched in scale and financial flexibility by capitalized peers.[15, 17] Because DHC is focused entirely on organic recovery and deleveraging, it cannot participate in market-expanding acquisitions.[11] Welltower and Ventas are actively deploying billions of dollars in equity-funded senior housing acquisitions, capturing premium assets in high-growth submarkets.[16, 18]
DHC risks being competitively marginalized in key metropolitan statistical areas (MSAs) if competitors acquire local high-performing clusters and achieve superior regional scale and labor procurement efficiencies.[12, 15]
On the balance sheet, DHC’s 7.8x leverage is a critical vulnerability.[11] Any disruption in operational performance or a prolonged period of high interest rates would severely elevate the cost of refinancing DHC's debt as the 2028 maturity wall approaches.[11, 13]
Within the SHOP segment, DHC does not lease properties but rather operates under management agreements.[3, 9] Consequently, DHC bears the ultimate credit and operational risk of these communities.[3]
In the medical office and life science portfolio, DHC faces lease expiration risk.[11] Approximately 9% of annualized rental income in this portfolio is scheduled to expire through the end of 2026, with 304,000 square feet (representing 4.9% of annualized rental income) already known to be vacating by year-end.[11] Failure to rapidly re-lease this specialized lab and medical space would lead to immediate top-line erosion and elevated tenant improvement (TI) capital expenditures.[11, 13]
Senior housing communities are subject to extensive federal, state, and local regulation, including licensing, staffing ratios, and health and safety certifications.[13] Non-compliance can lead to severe financial penalties, operational suspensions, or the loss of Medicare/Medicaid eligibility.[13]
From a governance standpoint, DHC’s external management agreement with RMR presents continuous structural risks.[3, 9] Overlapping executive leadership—whereby DHC's CEO, CFO, and Trustees hold prominent executive roles and significant equity ownership within RMR and ABP Trust—creates potential conflicts of interest regarding management fees, property transactions, and capital allocation priorities.[3]
DHC is highly sensitive to labor inflation, wage growth, and utility cost fluctuations.[6, 13] Senior living communities are labor-intensive, requiring specialized nursing, administrative, and culinary staff.[6, 13] A return of acute nursing shortages would force operators to utilize expensive contract agency labor, severely compressing SHOP operating margins.[6, 11]
Furthermore, because real estate values are inversely correlated with cap rates, any systemic increase in interest rates would depress property valuations and complicate asset recycling programs.[13, 27]
│
├─► Early Warning: Spike in contract agency labor utilization & rising food/utility costs.
│ (SHOP NOI margin contraction below 12%)
│
└─► Thesis Damage: EBITDAre falls below $250M; net leverage escalates above 9.0x.
(Maturity wall in 2028 becomes un-refinancable, resulting in dilutive equity issuance)
To project DHC’s potential total return profile over a five-year horizon (ending in 2031), this report outlines a comprehensive High, Base, and Low case analysis. These projections are anchored on DHC’s current shares outstanding of 242.11 million, a current share price of \$9.24 (as of July 1, 2026), and the updated 2026 guidance midpoint of \$307.5 million in Adjusted EBITDAre.[5, 19, 33]
For each scenario, the projected common equity value is derived using the standard enterprise value formula:
$\text{Enterprise Value (EV)} = \text{Adjusted EBITDAre} \times \text{EV/EBITDAre Multiple}$$\text{Equity Value} = \text{EV} - \text{Net Debt}$$\text{Projected Share Price} = \frac{\text{Equity Value}}{\text{Shares Outstanding}}$
The Base Case assumes a successful operational turnaround of the transitioned SHOP portfolio, with occupancy rising from the current same-property level of 82.4% and stabilizing at 88.0% over the next five years.[8, 11]
The High Case assumes an optimized macro environment where DHC benefits from the full force of the demographic "Silver Tsunami" alongside severe local undersupply.[5, 12]
The Low Case assumes a highly adverse scenario characterized by persistent wage inflation, severe nursing labor shortages, and failure to drive occupancy in the transitioned SHOP portfolio.[8, 13]
The following table models the annual share price trajectory for each scenario from Year 0 to Year 5, based on the fundamental valuation bridges detailed above [33]:
| Year | High Case Share Price (USD) | Base Case Share Price (USD) | Low Case Share Price (USD) |
|---|---|---|---|
| Year 0 (2026) | \$9.24 | \$9.24 | \$9.24 |
| Year 1 (2027) | \$12.00 | \$10.50 | \$7.50 |
| Year 2 (2028) | \$15.50 | \$12.00 | \$6.00 |
| Year 3 (2029) | \$20.00 | \$13.75 | \$4.50 |
| Year 4 (2030) | \$25.50 | \$15.65 | \$3.50 |
| Year 5 (2031) | \$32.07 | \$17.82 | \$2.52 |
The following table synthesizes the fundamental drivers, valuation parameters, and returns for each of the three modeled scenarios [5, 17, 19, 33]:
| Scenario | Revenue in Year 5 | Margin / EBITDAre Assumption | Valuation Multiple Assumption | Current Share Price | Implied Future Share Price | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | \$2.20 Billion | 28.0% Margin / \$617.1M EBITDAre | 15.0x EV / EBITDAre | \$9.24 USD | \$32.07 USD | 247.1% | 28.3% | 25% |
| Base Case | \$1.91 Billion | 25.0% Margin / \$478.5M EBITDAre | 13.0x EV / EBITDAre | \$9.24 USD | \$17.82 USD | 92.9% | 14.0% | 60% |
| Low Case | \$1.58 Billion | 18.0% Margin / \$284.4M EBITDAre | 10.0x EV / EBITDAre | \$9.24 USD | \$2.52 USD | -72.7% | -22.7% | 15% |
ASYMMETRIC TURNAROUND POTENTIAL
DHC’s operational, financial, and strategic qualities have been evaluated on a scale of 1 to 10, assessing the key metrics that govern its mid-to-long-term viability:
Qualitative Category Ratings (Scale 1-10):
Management Alignment [■■■□□□□□□□] 3/10
Revenue Quality [■■■■■■■□□□] 7/10
Market Position [■■■■■□□□□□] 5/10
Growth Outlook [■■■■■■■■□□] 8/10
Financial Health [■■■■□□□□□□] 4/10
Business Viability [■■■■■■□□□□] 6/10
Capital Allocation [■■■■■□□□□□] 5/10
Analyst Sentiment [■■■■■■■□□□] 7/10
Profitability [■■■■□□□□□□] 4/10
Track Record [■■■□□□□□□□] 3/10
Blended Overall Score: 5.2 / 10
Management alignment with common shareholders is structurally weak.[3, 19] DHC is externally managed by RMR, which charges fees based on real estate costs and market capitalization rather than per-share metrics.[3, 29] Insiders and individual trustees hold only 0.57% of outstanding shares directly, minimizing skin in the game.[19] Furthermore, the incentive management fee structure has historically introduced substantial G&A overhead that penalizes bottom-line profitability during periods of rising stock prices.[11, 31]
Revenue quality is healthy and bifurcated.[6, 7] The medical office and life science portfolio delivers high-quality, long-term contracted rental streams with high retention rates.[2, 6] Within the SHOP portfolio, revenue quality is highly operationally sensitive but benefits from a pure private-pay model, which minimizes government reimbursement risk and Medicare/Medicaid payment cycles.[5, 6]
DHC maintains an intermediate market position.[17, 28] While it lacks the scale of dominant national operators like Welltower or Ventas, DHC possesses a geographically diverse regional platform of 285 properties across 33 states.[5, 17] The transition to regional operators has helped stabilize market share locally, though its financial constraints prevent it from bidding on institutional-quality acquisitions.[10, 11]
The macro growth outlook is exceptionally strong.[5, 12] The senior housing sector is entering its strongest demand decade in history as the 80+ cohort expands at 29% over five years, while new inventory additions remain at historical lows of 0.5%.[12] This severe supply constraint guarantees multi-year pricing power and occupancy tailwinds.[5, 12]
DHC's financial health remains constrained.[11, 19] Despite a recent credit upgrade by Moody's to B3 with a positive outlook, the company’s net debt-to-EBITDAre of 7.8x is significantly elevated relative to its peer group.[11] However, liquidity of \$272 million and the absence of any debt maturities until 2028 mitigate immediate default risks.[11, 27]
The long-term viability of DHC’s underlying real estate is high, given that medical research spaces and senior housing facilities fulfill essential, inelastic demand.[2, 12] The primary structural choke point is the external management fee structure and high corporate leverage, which could restrict capital reinvestment if credit markets tighten.[3, 13]
Capital allocation has transitioned to a conservative, rational model.[11] Management has correctly halted external acquisitions, focusing instead on internal capital expenditures such as the \$20 million wing conversion pipeline.[11] However, past capital allocation was highly value-destructive, necessitating massive asset liquidations at cyclical lows to address the 2026 debt maturities.[14, 27]
Analyst sentiment has turned bullish following the June 1 guidance revision.[20, 24] Major research houses have upgraded the stock, with price targets raised to a consensus average of \$9.83.[25] Zacks recently upgraded DHC to a Rank #2 (Buy), reflecting an upward trend in earnings estimate revisions.[24, 34]
On a GAAP basis, DHC remains unprofitable, reporting a net loss of \$43.3 million in Q1 2026.[7, 20] However, cash-flow-based profitability is positive, as evidenced by a Normalized FFO of \$0.14 per share and Adjusted EBITDAre of \$74.0 million.[8, 11] The net profit margins are heavily depressed by non-cash depreciation charges of \$62.9 million and interest expenses of \$37.0 million.[7]
Historically, DHC has a poor record of shareholder value creation, highlighted by its failed, highly contested merger attempt with Office Properties Income Trust (OPI) in 2023.[35, 36] However, the current management team’s 2025/2026 turnaround execution is highly positive, achieving a 113% total shareholder return in fiscal year 2025.[10, 27]
HIGH-YIELD OPERATIONAL TURNAROUND
The core investment thesis for Diversified Healthcare Trust represents a classic, highly leveraged operational turnaround set against the strongest senior housing demographic tailwinds in a generation.[10, 12] DHC’s successful transition of its senior living communities to localized regional operators in late 2025 has begun generating substantial cost efficiencies and occupancy gains, prompting a major guidance increase on June 1, 2026.[5, 10]
The primary catalysts for DHC over the next 12 to 24 months include:
* SHOP Occupancy Convergence: DHC’s same-property SHOP occupancy of 82.4% has substantial room to expand toward the historical peak of 92%.[8, 12] Given the high operating leverage of senior housing, every 100 basis point gain in occupancy generates disproportionate cash flow that flows directly to Normalized FFO.[5, 11]
* High-ROI Capital Conversion Pipeline: The execution of the initial \$20 million wing conversion projects is expected to generate mid-teens returns and add immediately accretive, high-margin assisted living units.[11]
* Balance Sheet Deleveraging: As Adjusted EBITDAre grows toward the updated FY 2026 range of \$300 million to \$315 million, DHC’s net leverage will naturally contract from 7.8x, paving the way for further credit rating upgrades and lower cost of capital.[5, 11]
However, these positive catalysts must be balanced against systemic risks.[13, 20] DHC's 7.8x leverage remains a key concern, leaving the equity highly vulnerable to macroeconomic shocks, wage inflation, and refinancing risks ahead of the 2028 debt maturity wall.[11, 13]
Additionally, the external management fee structure with RMR continues to act as a drag on G&A overhead, limiting full alignment with common shareholders.[3, 11] DHC's valuation reflects these constraints, trading at a discount to peers.[17, 28]
For investors willing to accept elevated corporate leverage and external management risk, DHC represents a highly asymmetric vehicle to capture the structural demand-supply imbalance of the senior housing sector.[11, 12]
COILED SPRING TURNAROUND
DHC’s stock exhibits strong upward momentum, trading at \$9.24 as of July 1, 2026, which is comfortably above its 200-day simple moving average of \$8.865.[33, 37] The stock has achieved a year-to-date gain of approximately 92.16% and has risen 161.79% over the past year, reflecting robust technical strength and consistent outperformance of the broader REIT sector.[20, 38]
In the short term, technical indicators present a neutral-to-oversold picture following a slight consolidation from its recent 52-week high of \$9.62, with the 14-day RSI sitting at 41.67.[20, 37]
The near-term price action will likely consolidate around current levels as the market digests DHC’s removal from the Russell 3000E and Microcap indices on June 27, 2026, before continuing its upward trajectory toward the average analyst price target of \$9.83.[20, 25]
STRONG BULLISH MOMENTUM
View Diversified Healthcare Trust (DHC) stock page
Loading the interactive version of this report…